Incyte Corporation (INCY) : The consensus on Incyte Corporation (INCY) based on 13 analyst recommendation on the company stock is 1.27, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 10 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Incyte Corporation (INCY) : 11 Wall Street analysts covering Incyte Corporation (INCY) believe that the average level the stock could reach for the short term is $97.64. The maximum price target given is $135 and the minimum target for short term is around $85, hence the standard deviation is calculated at $14.58.
For the current week, the company shares have a recommendation consensus of Buy. Incyte Corporation (NASDAQ:INCY): The stock opened at $83.50 on Thursday but the bulls could not build on the opening and the stock topped out at $83.73 for the day. The stock traded down to $80.49 during the day, due to lack of any buying support eventually closed down at $81.21 with a loss of -2.73% for the day. The stock had closed at $83.49 on the previous day. The total traded volume was 1,712,304 shares.
In a related news, The Securities and Exchange Commission has divulged that Huber Reid M, officer (EVP, Chief Scientific Officer) of Incyte Corp, had unloaded 10,000 shares at an average price of $87.96 in a transaction dated on August 2, 2016. The total value of the transaction was worth $879,600.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f